[go: up one dir, main page]

BR112014022780A8 - composto modulador de receptor de fígado x, composição farmacêutica que o compreende e seu uso - Google Patents

composto modulador de receptor de fígado x, composição farmacêutica que o compreende e seu uso

Info

Publication number
BR112014022780A8
BR112014022780A8 BR112014022780A BR112014022780A BR112014022780A8 BR 112014022780 A8 BR112014022780 A8 BR 112014022780A8 BR 112014022780 A BR112014022780 A BR 112014022780A BR 112014022780 A BR112014022780 A BR 112014022780A BR 112014022780 A8 BR112014022780 A8 BR 112014022780A8
Authority
BR
Brazil
Prior art keywords
liver
pharmaceutical composition
modulator compound
receptor modulator
receptor
Prior art date
Application number
BR112014022780A
Other languages
English (en)
Other versions
BR112014022780A2 (pt
Inventor
Chengguo Dong
Yi Fan
Katerina Leftheris
Stephen Lotesta
Suresh B Singh
Colin Tice
Wei Zhao
Yajun Zheng
Linghang Zhuang
Original Assignee
Vitae Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitae Pharmaceuticals Inc filed Critical Vitae Pharmaceuticals Inc
Publication of BR112014022780A2 publication Critical patent/BR112014022780A2/pt
Publication of BR112014022780A8 publication Critical patent/BR112014022780A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)

Abstract

composto modulador de receptor de fígado x, composição farmacêutica que o compreende e seu uso. a presente invenção refere-se a novos compostos e sais farmaceuticamente aceitáveis dos mesmos que são moduladores de receptor de fígado x. também são fornecidas composições que compreendem compostos da invenção e um veículo. adicionalmente, uso dos compostos aqui e métodos para o tratamento de uma doença ou distúrbio associado com o fígado x receptor são também descritos.
BR112014022780A 2012-03-16 2013-03-14 composto modulador de receptor de fígado x, composição farmacêutica que o compreende e seu uso BR112014022780A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261612063P 2012-03-16 2012-03-16
PCT/US2013/031250 WO2013138568A1 (en) 2012-03-16 2013-03-14 Liver x reception modulators

Publications (2)

Publication Number Publication Date
BR112014022780A2 BR112014022780A2 (pt) 2017-06-20
BR112014022780A8 true BR112014022780A8 (pt) 2021-06-15

Family

ID=47997958

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014022780A BR112014022780A8 (pt) 2012-03-16 2013-03-14 composto modulador de receptor de fígado x, composição farmacêutica que o compreende e seu uso

Country Status (27)

Country Link
US (5) US9073931B2 (pt)
EP (1) EP2825542B1 (pt)
JP (3) JP6114815B2 (pt)
KR (1) KR102069913B1 (pt)
CN (1) CN104203950B (pt)
AU (1) AU2013232069B2 (pt)
BR (1) BR112014022780A8 (pt)
CA (1) CA2865639C (pt)
CY (1) CY1118323T1 (pt)
DK (1) DK2825542T3 (pt)
EA (1) EA026431B1 (pt)
ES (1) ES2607113T3 (pt)
HR (1) HRP20161690T1 (pt)
HU (1) HUE030785T2 (pt)
IL (2) IL234301A (pt)
LT (1) LT2825542T (pt)
ME (1) ME02660B (pt)
MX (1) MX354820B (pt)
NZ (1) NZ629189A (pt)
PL (1) PL2825542T3 (pt)
PT (1) PT2825542T (pt)
RS (1) RS55532B1 (pt)
SG (1) SG11201405323YA (pt)
SI (1) SI2825542T1 (pt)
SM (2) SMT201700009T1 (pt)
WO (1) WO2013138568A1 (pt)
ZA (1) ZA201406390B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6114814B2 (ja) * 2012-03-16 2017-04-12 ヴァイティー ファーマシューティカルズ，インコーポレイテッド 肝臓ｘレセプターモジュレーター
HRP20161690T1 (hr) 2012-03-16 2017-02-24 Vitae Pharmaceuticals, Inc. Modulatori jetrenog receptora x
WO2015106164A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
WO2015195922A1 (en) * 2014-06-19 2015-12-23 Vitae Pharmaceuticals, Inc. Compounds for use in treating acute coronary syndrome and related conditions
AU2015301207B2 (en) * 2014-08-07 2020-01-30 Vitae Pharmaceuticals, Llc Piperazine derivatives as liver X receptor modulators
US10239849B2 (en) 2015-11-12 2019-03-26 Merck Sharp & Dohme Corp. Cyanopyridine derivatives as liver X receptor beta agonists, compositions, and their use
AU2017207291B2 (en) 2016-01-11 2023-06-15 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
CN109661238B (zh) 2016-07-27 2023-07-25 哈里斯制药公司 治疗红细胞疾病的治疗组合
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
WO2019222265A1 (en) 2018-05-15 2019-11-21 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase
EP3931349B8 (en) * 2019-02-28 2025-01-15 The Rockefeller University Apoe genotyping in cancer prognostics and treatment
WO2021009664A1 (en) 2019-07-15 2021-01-21 Novartis Ag Methods for treating meibomian gland dysfunction with liver x receptor agonists
WO2021119397A1 (en) 2019-12-13 2021-06-17 Rgenix, Inc. Metal salts and uses thereof

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748247A (en) 1986-10-21 1988-05-31 American Home Products Corporation 2-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]alkyl]alkyl]pyrido- and pyrazino-indole-1,3-dione derivatives as histamine H1 antagonists
AU7165591A (en) 1990-01-22 1991-08-05 E.I. Du Pont De Nemours And Company Herbicidal sulfonylureas
EP0572863A1 (de) 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag ZNS Pyrazinoindole
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
ATE290378T1 (de) 1993-12-23 2005-03-15 Lilly Co Eli Proteinkinase c-inhibitoren
WO1996012721A1 (en) 1994-10-20 1996-05-02 American Home Products Corporation Indole derivatives useful as serotonergic agents
EP0912513A1 (en) 1996-06-28 1999-05-06 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
JP2000514061A (ja) 1996-06-28 2000-10-24 メルク エンド カンパニー インコーポレーテッド フィブリノーゲン受容体拮抗物質
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2257937A1 (en) 1996-06-28 1998-01-08 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US6177440B1 (en) 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
FR2761073B1 (fr) 1997-03-20 1999-04-23 Synthelabo Derives de pyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
FR2761070B1 (fr) 1997-03-20 1999-04-23 Synthelabo Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
DE19802235A1 (de) 1998-01-22 1999-07-29 Bayer Ag Mit tricyclischen Indolen substituierte Oxazolidinone
IL129484A0 (en) 1998-04-17 2000-02-29 Lilly Co Eli Substituted tricyclics
MXPA01011173A (es) 1999-05-06 2002-04-24 Neurogen Corp 4-0x0-quinolin-3-carboxamidas sustituidas: ligandos del receptor cerebro de gaba.
US7037916B2 (en) 1999-07-15 2006-05-02 Pharmacopeia Drug Discovery, Inc. Pyrimidine derivatives as IL-8 receptor antagonists
IT1313593B1 (it) * 1999-08-03 2002-09-09 Novuspharma Spa Derivati di 1,2-diidro-1-oxo-pirazino 1,2-a indolo.
WO2001030331A2 (en) 1999-10-22 2001-05-03 Eli Lilly And Company Therapeutic compositions including protein kinase c inhibitors
CA2396257A1 (en) 2000-01-06 2001-07-12 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Novel compounds and compositions as protease inhibitors
AU8395501A (en) 2000-07-31 2002-02-13 Hoffmann La Roche Piperazine derivatives
JP2005506280A (ja) 2000-12-20 2005-03-03 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー アリールおよびアミノアリール置換セロトニン受容体アゴニストおよびアンタゴニストリガンド
GB0106177D0 (en) * 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
FR2829766A1 (fr) 2001-09-14 2003-03-21 Lipha Derives d'oxamates comportant un heterocycle azote diversement substitue
MXPA04006123A (es) 2001-12-21 2004-11-01 King Pharmaceuticals Res & Dev Derivados de tirosilo y su uso como moduladores de receptores p2x7.
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
DE10320780A1 (de) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
EP1714961B1 (en) 2004-02-12 2015-12-09 Mitsubishi Tanabe Pharma Corporation Indazole compound and pharmaceutical use thereof
CA2560311A1 (en) 2004-04-08 2005-10-20 Novartis Ag Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejection
RU2266906C1 (ru) 2004-04-29 2005-12-27 Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
WO2005113526A2 (en) 2004-05-21 2005-12-01 Pfizer Products Inc. Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
EP1828200B1 (en) 2004-12-15 2010-02-17 F. Hoffmann-Roche AG Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer's disease.
CA2593266A1 (en) 2005-01-03 2006-07-13 Universita Degli Studi Di Siena Aryl piperazine derivatives for the treatment of neuropsychiatric disorders
US7790712B2 (en) 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
PL1904477T3 (pl) 2005-07-14 2009-07-31 Hoffmann La Roche Pochodne indolo-3-karbonylo-spiro-piperydyny jako antagoniści receptora V1a
WO2007035841A1 (en) 2005-09-21 2007-03-29 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP1779848A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
JP4882127B2 (ja) * 2005-11-16 2012-02-22 株式会社ジェイテクト 位置調整式ステアリング装置
JP2007137810A (ja) * 2005-11-17 2007-06-07 Sankyo Co Ltd インドール化合物を含有する医薬
ES2333672T3 (es) 2005-12-09 2010-02-25 F. Hoffmann-La Roche Ag Derivados de amida triciclica para tratamiento de obesidad.
US7351706B2 (en) 2006-01-05 2008-04-01 Hoffmann-La Roche Inc. Indol-3-yl-carbonyl-spiro-piperidine derivatives
FR2897061B1 (fr) 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
WO2008122115A1 (en) 2007-04-09 2008-10-16 Methylgene Inc. Inhibitors of histone deacetylase
US20110002855A1 (en) 2007-06-25 2011-01-06 Neurogen Corporation Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
EP2205085A1 (en) 2007-09-25 2010-07-14 Merck Sharp & Dohme Corp. 2-aryl or heteroaryl indole derivatives
CN101456863B (zh) * 2007-12-14 2012-04-25 华北制药集团新药研究开发有限责任公司 Lxr激动剂及其制备方法和用途
CN101952293A (zh) * 2007-12-21 2011-01-19 惠氏有限责任公司 吡唑并[1,5-a]嘧啶化合物
NZ587215A (en) 2008-01-22 2012-08-31 Takeda Pharmaceutical Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
US20090192147A1 (en) 2008-01-30 2009-07-30 Wyeth [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
US8207165B2 (en) 2008-03-28 2012-06-26 Nerviano Medical Sciences S.R.L. 3,4-dihydro-2H-pyrazino[1,2-A]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
TW201031665A (en) 2009-02-04 2010-09-01 Gruenenthal Gmbh Substituted indole-compound
AU2010257856A1 (en) 2009-06-08 2011-11-03 Grünenthal GmbH Substituted benzimidazoles, benzothiazoles and benzoxazoles
WO2011005295A1 (en) 2009-06-24 2011-01-13 Arena Pharmaceuticals, Inc. Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
AU2010292287A1 (en) 2009-09-11 2012-03-15 Sunovion Pharmaceuticals Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof
JP5643332B2 (ja) 2009-12-07 2014-12-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピロロピリジンまたはベンゾイミダゾールコアを含有する複素環化合物
US20130045203A1 (en) 2010-03-02 2013-02-21 Emory University Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP
KR101302474B1 (ko) * 2012-02-20 2013-09-02 주식회사 케이씨씨 내충격성 및 불연성이 우수한 진공단열재용 봉지부재
HRP20161690T1 (hr) * 2012-03-16 2017-02-24 Vitae Pharmaceuticals, Inc. Modulatori jetrenog receptora x
JP6114814B2 (ja) * 2012-03-16 2017-04-12 ヴァイティー ファーマシューティカルズ，インコーポレイテッド 肝臓ｘレセプターモジュレーター

Also Published As

Publication number Publication date
CN104203950A (zh) 2014-12-10
SI2825542T1 (sl) 2017-01-31
LT2825542T (lt) 2016-12-27
CA2865639C (en) 2020-12-22
HRP20161690T1 (hr) 2017-02-24
AU2013232069B2 (en) 2017-07-13
PL2825542T3 (pl) 2017-05-31
DK2825542T3 (en) 2017-01-09
CA2865639A1 (en) 2013-09-19
US9073931B2 (en) 2015-07-07
US20150065515A1 (en) 2015-03-05
AU2013232069A1 (en) 2014-09-18
US20200138812A1 (en) 2020-05-07
US20180117041A1 (en) 2018-05-03
PT2825542T (pt) 2016-12-20
IL234301A (en) 2017-09-28
CN104203950B (zh) 2016-08-24
US20170007603A1 (en) 2017-01-12
MX2014011104A (es) 2014-12-05
JP2019006813A (ja) 2019-01-17
HK1206332A1 (en) 2016-01-08
RS55532B1 (sr) 2017-05-31
SG11201405323YA (en) 2014-10-30
US9707232B2 (en) 2017-07-18
JP2017128589A (ja) 2017-07-27
EA026431B1 (ru) 2017-04-28
BR112014022780A2 (pt) 2017-06-20
NZ629189A (en) 2016-08-26
MX354820B (es) 2018-03-21
HUE030785T2 (en) 2017-06-28
WO2013138568A1 (en) 2013-09-19
US9416135B2 (en) 2016-08-16
WO2013138568A8 (en) 2014-08-28
JP2015514061A (ja) 2015-05-18
JP6114815B2 (ja) 2017-04-12
ES2607113T3 (es) 2017-03-29
SMT201700009T1 (it) 2017-03-08
ZA201406390B (en) 2019-11-27
EP2825542A1 (en) 2015-01-21
KR102069913B1 (ko) 2020-01-23
CY1118323T1 (el) 2017-06-28
IL251897A0 (en) 2017-06-29
EA201491610A1 (ru) 2014-12-30
EP2825542B1 (en) 2016-09-14
ME02660B (me) 2017-06-20
US20150336963A1 (en) 2015-11-26
KR20140135829A (ko) 2014-11-26
SMT201700009B (it) 2017-03-08

Similar Documents

Publication Publication Date Title
BR112014022780A8 (pt) composto modulador de receptor de fígado x, composição farmacêutica que o compreende e seu uso
BR112015022417A2 (pt) métodos e composições para inibição de proteínas contendo bromodomínio
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
BR112014021531A2 (pt) composto, composição farmacêutica e usos dos mesmos
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
BR112016000975A8 (pt) esteróides neuroativos, composições os compreendendo e uso dos mesmos
CL2015001733A1 (es) Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
GT201500092A (es) Moduladores de quinolinillo unidos a fenilo de ror-gamma-t
CO7160104A2 (es) Inhibidores de virus de hepatitis c
BR112015022785A2 (pt) composto; composição farmacêutica; kit ou artigo farmacêutico embalado; método de inibição de uma arginina metil transferase (rmt); método de modulação da expressão genética; método de modulação da transcrição; e método de tratamento de um distúrbio mediado por rmt
BR112015001613A8 (pt) Compostos que são agentes de modulação de s1p e/ou agentes de modulação de atx, seus usos e composição farmacêutica
BR112016028835A2 (pt) derivados de auristatina e conjugados dos mesmos
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
BR112015007061A8 (pt) composto, composição farmacêutica e uso do composto
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
BR112016014020A2 (pt) Compostos moduladores de tetra-hidropiridopirazinas de gpr6, seus sais e os usos dos mesmos
BR112014030655A8 (pt) Compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende
BR112015011031A2 (pt) moduladores de grp40 de di-hidropirazol
BRPI1013259B8 (pt) moduladores lxr
BR112012024822B8 (pt) Composto, uso de um composto e composição farmacêutica
BR112017018305A2 (pt) desacetoxitubulisina h e análogos da mesma
BR112017001968A2 (pt) embalagem de duas câmaras para uma composição farmacêutica líquida oral de múltiplas doses
BR112014025041B8 (pt) Composição farmacêutica
IN2014DN07636A (pt)
BR112014019704A8 (pt) Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: VITAE PHARMACEUTICALS, INC. (US)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: VITAE PHARMACEUTICALS, LLC (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements